Ozempic’s hidden pregnancy risk few women know about

A groundbreaking new study from Flinders University has brought to light a critical public health concern, revealing that a significant majority of Australian women of reproductive age who are prescribed GLP-1 receptor agonists – a class of medications increasingly popular for weight loss, including well-known drugs like Ozempic – are not simultaneously using effective contraception. This oversight occurs despite established warnings regarding the potential risks these medications pose during pregnancy to both the mother and the developing fetus.

Published in the esteemed Medical Journal of Australia, the comprehensive research delved into an extensive dataset, analyzing records from over 1.6 million women aged 18 to 49 who attended general practices across Australia between 2011 and 2022. The findings are stark: among the 18,010 women identified as having received a first-time prescription for GLP-1 receptor agonists during this period, a mere 21% had reported using any form of contraception. This significant gap in reproductive health planning raises alarms among medical professionals and underscores an urgent need for enhanced patient education and clearer clinical guidelines.

The Rise of GLP-1 Receptor Agonists: From Diabetes Management to Weight Loss Phenomenon

Glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed and approved for the management of type 2 diabetes. Their mechanism of action involves mimicking the natural GLP-1 hormone, which stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes a feeling of satiety, thereby aiding in blood sugar control and weight reduction. Medications such as liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy) have been instrumental in improving outcomes for diabetic patients.

However, over the past decade, the potent weight-loss effects of these drugs have propelled them into the mainstream as a highly sought-after solution for obesity and overweight conditions. This surge in popularity has led to a dramatic increase in prescriptions, often for individuals without a diabetes diagnosis, reflecting a broader societal shift towards pharmacological interventions for weight management. The study by Flinders University precisely captures this evolving landscape, noting that most prescriptions for GLP-1 receptor agonists are now being issued to women who do not have type 2 diabetes.

Associate Professor Luke Grzeskowiak, a pharmacist and the lead author of the study from the College of Medicine and Public Health at Flinders University, highlighted the scale of this shift. "In 2022 alone, more than 6,000 women began treatment on GLP-1s, and strikingly, over 90% of those did not have a diabetes diagnosis," he stated. This statistic is particularly concerning when juxtaposed with the low rates of contraception use among this demographic. "We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care," Associate Professor Grzeskowiak emphasized, adding, "These medications can be incredibly helpful, but they’re not risk-free, especially during pregnancy."

Dissecting the Study’s Findings: Pregnancy Rates and Demographic Insights

The Flinders University research offers a granular view of pregnancy outcomes among women using GLP-1 receptor agonists. The study found that 2.2% of women became pregnant within six months of initiating GLP-1 treatment. While this percentage might seem modest at first glance, given the rapidly expanding user base, it translates into a substantial number of potentially exposed pregnancies.

The analysis further revealed interesting demographic patterns in pregnancy rates. The highest rates were observed among younger women who had a diagnosis of diabetes, suggesting that while the drug was prescribed for diabetes management, reproductive health counseling might still be inadequate in this group. Additionally, women without diabetes in their early thirties also exhibited higher pregnancy rates, indicating that the focus on weight loss might overshadow discussions about fertility and contraception in this age group.

A particularly noteworthy finding from the study pertains to women with polycystic ovary syndrome (PCOS). These women were twice as likely to conceive while on GLP-1 treatment. PCOS is a common endocrine disorder often associated with insulin resistance and obesity, which can impair fertility. The weight loss achieved through GLP-1 receptor agonists appears to improve metabolic parameters and, consequently, enhance fertility in women with PCOS, even when pregnancy is not actively being planned or desired. This "unintended improvement in fertility" presents a unique challenge, as it can lead to higher rates of unplanned pregnancies in a cohort already at risk.

Crucially, the study provided clear evidence that effective contraception acts as a protective factor. Women who were consistently using contraception at the time of receiving their GLP-1 prescription had a significantly lower risk of becoming pregnant. This underscores the importance of proactive reproductive planning and effective contraceptive methods when these medications are initiated.

The Known and Potential Risks to Pregnancy: A Call for Caution

The concern surrounding GLP-1 receptor agonists in pregnancy is not merely theoretical. While extensive human data is still accumulating, preliminary evidence and animal studies have raised significant red flags. A previous systematic review of animal studies conducted by the University of Amsterdam, for instance, linked GLP-1 exposure during pregnancy to adverse outcomes, including reduced fetal growth and skeletal abnormalities. These findings, while not directly translatable to humans, serve as a critical warning.

The precise mechanisms by which GLP-1 receptor agonists might harm a developing fetus are still under investigation. However, potential pathways include direct effects on fetal GLP-1 receptors, alterations in maternal nutrient metabolism impacting fetal supply, or indirect effects related to rapid maternal weight loss. Regulatory bodies globally, including the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States, typically advise against the use of these medications during pregnancy due to insufficient data to rule out risks. Many GLP-1 receptor agonists are classified as Category C or D for pregnancy, indicating that animal studies have shown adverse effects or there is positive evidence of human fetal risk, respectively. The general recommendation is to discontinue these medications several weeks or even months before attempting conception, given their half-life and potential lingering effects.

Associate Professor Grzeskowiak highlighted the discrepancy between international advice and Australian clinical practice. "Whilst the UK advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception, this advice is not being followed consistently in Australian clinical practice," he observed. This inconsistency points to a systemic gap in patient counseling and guideline implementation, potentially leaving a significant number of women vulnerable.

Broader Implications and Public Health Challenges

The findings of the Flinders University study carry profound implications for public health, medical ethics, and clinical practice. The rapid proliferation of GLP-1 receptor agonists, coupled with inadequate contraception counseling, creates a scenario where a growing number of pregnancies could potentially be exposed to medications with unknown, but potentially harmful, effects.

From an ethical standpoint, healthcare providers have a fundamental duty of care to ensure patients are fully informed about the risks and benefits of any prescribed medication, especially those with implications for reproductive health. The study suggests that this informed consent process may be falling short in the context of GLP-1 prescribing. Patient autonomy dictates that individuals make choices about their bodies and treatments based on complete and accurate information.

The fertility paradox observed in women with PCOS adds another layer of complexity. While improved fertility is often a positive outcome for many, if it leads to unplanned pregnancies in the context of GLP-1 use, it inadvertently places these pregnancies at risk. This necessitates a more nuanced approach to counseling, acknowledging both the therapeutic benefits and the potential reproductive consequences.

The sheer volume of prescriptions, particularly for off-label use in weight loss before specific approvals for weight management (e.g., Wegovy for semaglutide in weight management), means that a broad demographic of women of childbearing age is now exposed. This scale elevates the issue from individual patient care to a significant public health challenge, demanding a coordinated response from healthcare systems, regulatory bodies, and professional associations.

Calls to Action and Official Responses

In response to these critical findings, Associate Professor Grzeskowiak and his team have issued clear calls to action aimed at improving patient safety and ensuring responsible prescribing practices. "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age," he urged. This means integrating comprehensive discussions about contraception, pregnancy planning, and potential risks into every consultation where GLP-1 receptor agonists are considered.

Furthermore, there is an urgent need for clearer practice recommendations and guidelines for healthcare professionals prescribing GLP-1s to women. These guidelines should standardize the counseling process, emphasize the importance of effective contraception, and provide clear protocols for managing patients who become pregnant while on these medications. Professional bodies such as the Royal Australian College of General Practitioners (RACGP) and the Pharmaceutical Society of Australia (PSA) are likely to play a pivotal role in developing and disseminating such guidelines, as well as in providing ongoing education and training to their members.

Pharmacists, as readily accessible healthcare professionals, also have a critical role in reinforcing these messages and ensuring patients understand the risks. Their direct interaction with patients at the point of dispensing provides a crucial opportunity for counseling and risk mitigation.

Associate Professor Grzeskowiak’s advice to patients is unequivocal: "Our advice is to speak to your GP about the risks and benefits of GLP-1 medicines before taking them, and only take those prescribed by a healthcare professional." This emphasizes the importance of a patient-centered approach and discourages the use of unregulated or informally obtained medications.

From a regulatory perspective, the Therapeutic Goods Administration (TGA) may need to consider updating product information, issuing further advisories to healthcare professionals, or even launching public awareness campaigns to ensure that both prescribers and patients are fully informed about the reproductive risks associated with GLP-1 receptor agonists.

Future Research and Ongoing Monitoring

The authors of the Flinders University study rightly conclude that further studies evaluating the impact of these medications on pregnancy and unborn babies are warranted. The current limitations in human data highlight the pressing need for:

1. Pregnancy Registries: Establishing national and international pregnancy registries to systematically collect data on women exposed to GLP-1 receptor agonists during pregnancy, tracking outcomes for both mothers and babies.
2. Long-Term Follow-up: Monitoring children exposed in utero for any long-term developmental, metabolic, or other health issues.
3. Pharmacovigilance: Enhanced post-marketing surveillance to identify and analyze any adverse pregnancy outcomes reported in real-world clinical settings.
4. Mechanistic Studies: Further research into the precise biological mechanisms by which these drugs might affect fetal development.

The rapid adoption of GLP-1 receptor agonists for weight loss represents a significant medical advance, offering substantial benefits to many individuals. However, as with any powerful medication, understanding and mitigating potential risks, particularly during vulnerable periods like pregnancy, is paramount. The Flinders University study serves as a timely and vital reminder that while innovation in medicine progresses, vigilance in patient safety must remain at the forefront of clinical practice.

Acknowledgements: The research was supported by a Channel 7 Children’s Research Foundation Fellowship (CRF-210323) to Luke Grzeskowiak. The contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), funded by the National Health and Medical Research Council (APP2024717), are also acknowledged.